Novel antibody-drug conjugates targeting ERBB2-low subtypes of advanced breast cancer, such as trastuzumab deruxtecan, have led to longer progression-free survival and overall survival compared to chemotherapy [3,6]. This evidence concerns the gene ERBB2 and breast carcinoma.